<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182245</url>
  </required_header>
  <id_info>
    <org_study_id>1199.6</org_study_id>
    <nct_id>NCT02182245</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial were to determine the safety, tolerability, and MTD of
      BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BIBF 1120</measure>
    <time_frame>up to 126 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120</measure>
    <time_frame>up to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen 125 (CA-125) response</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumour progression (time from treatment start to the time of documented tumour progression)</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with the following histologically confirmed advanced gynaecological
             malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed
             Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical
             carcinoma or vulvular carcinoma

          -  Metastatic disease or locally advanced disease that is not resectable with curative
             intention

          -  Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the
             investigator

          -  Age 18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Life expectancy of at least 6 months

          -  Written informed consent that is not consistent with ICH-GCP (International Conference
             on Harmonisation - Good Clinical Practice) guidelines and local requirements

        Exclusion Criteria:

          -  Participation in another clinical study within the past 4 weeks before start of
             therapy or concomitantly with this study

          -  Radiotherapy within 4 weeks before the start of therapy

          -  Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal
             replacement therapy) within 4 weeks before the start of the therapy

          -  Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale
             de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO
             I-III), primary endometrial cancer (FIGO I-III) or borderline tumours

          -  Patients with known brain metastases

          -  Symptomatic bowel obstruction or known or suspected malabsorption

          -  Patients with pericardial effusion which is haemodynamically relevant

          -  Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin
             cancer or cervical carcinoma in situ)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study medication

          -  History of haemorrhagic or thrombotic event (including transient ischemic attacks) in
             the past 6 months

          -  Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low
             dose daily acetylsalicylic acid &lt;300 mg)

          -  Major injuries and surgeries within the past 3 weeks, planned surgical procedures
             during the trial, incomplete wound healing

          -  Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their
             excipients or vehicles such as polyoxyethylated castor oil

          -  Clinically significant peripheral polyneuropathy (&gt;CTCAE grade 1) which precludes
             therapy with paclitaxel

          -  Absolute neutrophil count (ANC) &lt;1500/μL, platelet count &lt;100000/μL, or haemoglobin &lt;9
             mg/dL

          -  Total bilirubin &gt;1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST
             (Aspartate aminotransferase) &gt;1.5 x the upper limit of normal (ULN)

          -  Serum creatinine &gt;1.5 mg/dL (&gt;132 μmol/L)

          -  Persistent gross haematuria

          -  Pregnancy or breast feeding

          -  Women with childbearing potential and who are sexually active and unwilling to use a
             medically acceptable method of contraception (oral contraceptive, diaphragm with
             spermicide, intrauterine device, condom with spermicide)

          -  Known or suspected active drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

